8-KEarnings & ResultsExhibits & Filings

AMGEN INC 8-K Report, Financial Results (Jan 23, 2013)

Filed January 23, 2013For Securities:AMGN

Summary

Amgen Inc. (AMGN) filed an 8-K on January 23, 2013, to report its unaudited financial results for the fourth quarter and full year ended December 31, 2012. The report primarily details the company's use of non-GAAP financial measures to provide investors with a supplemental view of its operational performance and financial condition, alongside its GAAP results. These non-GAAP measures adjust for various items including cost-saving initiatives, stock option expensing, acquisition-related expenses, amortization of acquired intangible assets, contingent consideration, legal proceedings, non-cash interest on convertible notes, and tax effects. Amgen emphasizes that these non-GAAP figures are not a substitute for GAAP but are intended to facilitate a more comparable analysis of financial performance across different periods and against internally developed assets. The company also reported Free Cash Flow (FCF) as a non-GAAP measure to indicate liquidity.

Key Highlights

  • 1Amgen reported its unaudited financial results for the fourth quarter and full year ended December 31, 2012.
  • 2The company utilized non-GAAP financial measures to provide supplemental information to investors, alongside standard GAAP reporting.
  • 3Key adjustments in non-GAAP measures include cost-saving initiatives, stock option expensing, acquisition-related expenses, and amortization of acquired product technology rights.
  • 4Non-GAAP metrics are presented to offer a clearer view of operating performance and financial condition, facilitating comparisons across periods.
  • 5Amgen also reported Free Cash Flow (FCF) as a non-GAAP metric to illustrate liquidity.
  • 6The report indicates the company's ongoing efforts to improve cost efficiencies in its operations.
  • 7The filing includes a press release dated January 23, 2013, as Exhibit 99.1, which contains the detailed financial results and non-GAAP reconciliations.

Frequently Asked Questions

This 8-K filing serves to report Amgen's unaudited financial results for the three and twelve months ended December 31, 2012, and its financial position as of December 31, 2012. A significant focus is on the company's use of non-GAAP financial measures to present its results.

Amgen adjusts for several items, including charges related to cost of sales (COS) from cost-saving initiatives, expensing of stock options, acquisition-related expenses, amortization of acquired product technology rights, contingent consideration costs, legal proceedings, non-cash interest expense on convertible notes, and various tax effects. The specific adjustments can vary between the three-month and twelve-month periods and between 2011 and 2012.

Amgen believes that its non-GAAP financial measures provide useful supplementary information to and facilitate additional analysis by investors. These measures are intended to offer a more comparable view of the company's performance across different periods, especially when certain expenses or events are not recurring or when comparing acquired assets to internally developed ones.

Amgen reports Free Cash Flow (FCF) as a non-GAAP financial measure. It is calculated by subtracting capital expenditures from cash flow from operations, both as determined in accordance with GAAP. The company uses FCF as an additional measure of liquidity.